ADULT AMBULATORY INFUSION ORDER
Ferumoxytol (FERAHEME) Infusion

Weight: _________ kg  Height: _________ cm

Allergies: ____________________________________________

Diagnosis Code: ____________________________  Patient to follow up with provider on date: _________________

**This plan will expire after 365 days at which time a new order will need to be placed**

GUIDELINES FOR ORDERING
1. Ferumoxytol is contraindicated in patients with a history of allergic reaction to any intravenous iron product.
2. Provider must order and obtain a ferritin prior to patient being scheduled for iron infusion. Labs drawn date: ____________
3. Ferumoxytol administration may alter magnetic resonance (MR) imaging, conduct anticipated MRI studies prior to use.
4. MR imaging alterations may persist for less than or equal to 3 months following use, with peak alterations anticipated in the first 2 days following administration.
5. If MR imaging is required within 3 months after administration, use T1- or proton density-weighted MR pulse sequences to decrease effect on imaging.
6. Do not use T2-weighted sequence MR imaging prior to 4 weeks following ferumoxytol administration.

NURSING ORDERS:
1. TREATMENT PARAMETERS – Hold treatment and notify provider if Ferritin greater than 300 ng/mL.
2. VITAL SIGNS – For Ferumoxytol infusion: Monitor and record vital signs at conclusion of infusion and immediately prior to discharge.
3. Patient may experience hypotension during infusion, ensure patient is in a reclined or semi-reclined position during the ferumoxytol infusion
4. Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following infusion. Hypersensitivity reactions have occurred in patients in whom a previous ferumoxytol dose was tolerated.
5. Remind patient to contact provider to set up lab draw, approximately 4 weeks after treatment infusion.
6. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.

MEDICATIONS: (select one)
ferumoxytol (FERAHEME) in sodium chloride 0.9 %, intravenous, administer over 15 minutes
   ☐ 510 mg, x 2 doses, Administer dose followed by repeat dose 3-8 days after.

AS NEEDED MEDICATIONS:
1. sodium chloride 0.9%, 500 mL, intravenous, AS NEEDED x1 dose for vein discomfort. Give concurrently with ferumoxytol
## HYPERSENSITIVITY MEDICATIONS:

1. **NURSING COMMUNICATION** – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (Policy HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.

2. **Diphenhydramine (Benadryl) injection, 25-50 mg, intravenous, AS NEEDED x1 dose for hypersensitivity reaction, Max dose 50 mg**

3. **Epinephrine HCl (Adrenalin) injection, 0.3 mg, intramuscular, AS NEEDED x1 dose for hypersensitivity reaction**

4. **Hydrocortisone sodium succinate (Solu-Cortef) injection, 100 mg, intravenous, AS NEEDED x1 dose for hypersensitivity reaction, Dilute vial by either pressing chamber for Act-O-Vial or diluting powder vial with 2 mL SWFI or NS for injection.**

5. **Famotidine (Pepcid), 20 mg, intravenous, AS NEEDED x1 dose, for hypersensitivity reaction**

By signing below, I represent the following:
I am responsible for the care of the patient (*who is identified at the top of this form*);
I hold an active, unrestricted license to practice medicine in: □ Oregon □ [State] (check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon);

My physician license number is # [MUST BE COMPLETED TO BE A VALID PRESCRIPTION]; and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

---

Provider signature: __________________________ Date/Time: __________________________
Printed Name: __________________________ Phone: __________________________ Fax: __________________________
OLC Central Intake Nurse:
Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient’s preferred clinic location:

- **Beaverton**
  OHSU Knight Cancer Institute
  15700 SW Greystone Court
  Beaverton, OR 97006
  Phone number: 971-262-9000
  Fax number: 503-346-8058

- **NW Portland**
  Legacy Good Samaritan campus
  Medical Office Building 3, Suite 150
  1130 NW 22nd Ave.
  Portland, OR 97210
  Phone number: 971-262-9600
  Fax number: 503-346-8058

- **Gresham**
  Legacy Mount Hood campus
  Medical Office Building 3, Suite 140
  24988 SE Stark
  Gresham, OR 97030
  Phone number: 971-262-9500
  Fax number: 503-346-8058

- **Tualatin**
  Legacy Meridian Park campus
  Medical Office Building 2, Suite 140
  19260 SW 65th Ave.
  Tualatin, OR 97062
  Phone number: 971-262-9700
  Fax number: 503-346-8058

Infusion orders located at: [www.ohsuknight.com/infusionorders](http://www.ohsuknight.com/infusionorders)